GSK, Genmab report strong ofatumumab data

So far, it looks like GlaxoSmithKline's $2.1 billion deal for HuMax-CD20 was money well spent. Inerim data from a Phase III study showed that the drug--now known as ofatumumab--met primary and secondary endpoints in two groups of chronic lymphocytic leukemia patients who did not respond to either methotrexate or TNF-alpha antagonist therapy. More than half of the subjects who received ofatumumab responded to the drug, and now the companies are hoping to submit the drug the FDA and EMEA this year. The drug is also being studied in patients with non-Hodgkin's lymphoma, rheumatoid arthritis and multiple sclerosis.

- see this release on the results
- here's the WSJ report

Related Articles:
Genmab maps Phase III strategy HuMax-CD20
Glaxo forges $2.1B deal for HuMax-CD20
Genmab reports positive RA data for HuMax-CD20
Genmab shares up on new antibody tech